<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2139">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133310</url>
  </required_header>
  <id_info>
    <org_study_id>HGMDI/21/204/03/63</org_study_id>
    <nct_id>NCT05133310</nct_id>
  </id_info>
  <brief_title>Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In general, the percentage of complete remissions is 85 - 90 % for acute lymphoid leukemia&#xD;
      (ALL). In developing countries, percentages are lower secondary to higher sepsis-related&#xD;
      mortality. Although the effect of statins on inflammatory response associated with sepsis has&#xD;
      been demonstrated, including an effect on bacterial proliferation in patients with a state of&#xD;
      immunosuppression, their effect has not been demonstrated so far in patients with&#xD;
      hemato-oncological cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Death associated with sepsis is one of the principal complications related to chemotherapy&#xD;
      treatment; there are currently no strategies to prevent its development besides the use of&#xD;
      prophylactic antibiotics or granulocyte colony stimulants to reduce the period of febrile&#xD;
      neutropenia. Most of the trials on the use of statins are retrospective with controversial&#xD;
      results and include patients with different clinical situations that conditioned the septic&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 19, 2021</start_date>
  <completion_date type="Anticipated">June 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinical randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Discharge</measure>
    <time_frame>3 months</time_frame>
    <description>The event in which patient is discharge from Hospital stay,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feverish Event</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of a temperature above 38 ° persistently for more than 30 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sepsis</measure>
    <time_frame>3 months</time_frame>
    <description>Presence of hemodynamic alterations characterized by persistent hypotension, elevated heart rate, fever, and abnormal respiration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophils count</measure>
    <time_frame>3 months</time_frame>
    <description>Number of neutrophils found in peripheral blood at the end of each chemotherapy cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelets count</measure>
    <time_frame>3 month</time_frame>
    <description>Number of platelets found in peripheral blood at the end of each chemotherapy cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blasts in marrow</measure>
    <time_frame>3 month</time_frame>
    <description>Presence of more than 5% of blasts in bone marrow after each chemotherapy cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophil recovery time</measure>
    <time_frame>1 month</time_frame>
    <description>Time in days for neutrophil recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacterial isolation</measure>
    <time_frame>3 months</time_frame>
    <description>Description of the germ isolated in cultures during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin</measure>
    <time_frame>3 months</time_frame>
    <description>Biomarker used in infectious and inflammatory processes associated mainly with gram-negative germs, this measurement is routine in the follow-up of individuals with febrile neutropenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Stay</measure>
    <time_frame>1 month</time_frame>
    <description>Measurement of days of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Strains</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Standard Care Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive the standard chemotherapy regimen assigned for their treatment and, they will be followed and monitored until the end of treatment and hospitalization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will combine the standard CALGB treatment scheme plus Simvastatin 10mg orally every 24 hours during the first 7 days of treatment and then continue with 20mg every 24 hours until the end of treatment and hospitalization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Combination of Simvastatin with Standard Chemotherapy scheme for acute lymphoblastic patients.</description>
    <arm_group_label>Simvastatin Treatment Group</arm_group_label>
    <other_name>Intervention Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with acute leukemia under treatment of a chemotherapy regimen&#xD;
&#xD;
          -  Stable performance status (ECOG: 0 or Karnofsky scale greater than 80%) at time of&#xD;
             analysis and under chemotherapy regimen&#xD;
&#xD;
          -  Life expectancy greater than 48 hours after diagnosis&#xD;
&#xD;
          -  Oral route available&#xD;
&#xD;
          -  Have signed informed consent at the time of the study&#xD;
&#xD;
          -  Patients whose chemotherapy regimen is administered in a hospital rather than an&#xD;
             outpatient manner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute leukemias over 55 years of age and with impaired functional status&#xD;
             at the time of diagnosis&#xD;
&#xD;
          -  Elevation of liver enzymes 3 times higher than the range established by the central&#xD;
             laboratory&#xD;
&#xD;
          -  Persistent kidney involvement despite having adequate hydration&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Patients with peripheral neuropathy considered severe or disabling grade&#xD;
&#xD;
          -  Patients with a history of psychiatric disorders or psychotic attacks&#xD;
&#xD;
          -  Individuals who do not have the oral route available, who are maintained with a&#xD;
             nasogastric tube, or who require support for the diagnosis through parenteral&#xD;
             nutrition&#xD;
&#xD;
          -  Patients undergoing peritoneal dialysis or hemodialysis treatment&#xD;
&#xD;
          -  Patients with leukemia associated with Down syndrome&#xD;
&#xD;
          -  Patients under low-intensity chemotherapy regimen or palliative regimen&#xD;
&#xD;
          -  Previous allergy to any statin component&#xD;
&#xD;
          -  Patients with a history of liver failure (Child-Pugh Stage B or C)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adolfo Martinez Tovar, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General de Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian O Ramos Peñafiel, PhD</last_name>
    <phone>+52 55 27892000</phone>
    <phone_ext>2020</phone_ext>
    <email>leukemiachop@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adan G Gallardo Rodriguez, MSc</last_name>
    <phone>+52 55 27892000</phone>
    <phone_ext>2020</phone_ext>
    <email>nutriologo.agallardo8@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de México &quot;Dr. Eduardo Liceaga&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian O Ramos Peñafiel, PhD</last_name>
      <phone>+52 55 2789 2000</phone>
      <phone_ext>2020</phone_ext>
      <email>leukemiachop@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Adan G Gallardo-Rodriguez, MSc</last_name>
      <phone>+52 55 2789 2000</phone>
      <phone_ext>2020</phone_ext>
      <email>nutriologo.agallardo8@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Martínez Murillo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Humberto Castellanos Sinco, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Odín de la Mora Estrada, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Escrihuela-Vidal F, Laporte J, Albasanz-Puig A, Gudiol C. Update on the management of febrile neutropenia in hematologic patients. Rev Esp Quimioter. 2019 Sep;32 Suppl 2:55-58. Review.</citation>
    <PMID>31475812</PMID>
  </reference>
  <reference>
    <citation>Pirzad Jahromi G, P Shabanzadeh A, Mokhtari Hashtjini M, Sadr SS, Rasouli Vani J, Raouf Sarshoori J, Charish J. Bone marrow-derived mesenchymal stem cell and simvastatin treatment leads to improved functional recovery and modified c-Fos expression levels in the brain following ischemic stroke. Iran J Basic Med Sci. 2018 Oct;21(10):1004-1012. doi: 10.22038/IJBMS.2018.29382.7100.</citation>
    <PMID>30524673</PMID>
  </reference>
  <reference>
    <citation>Pertzov B, Eliakim-Raz N, Atamna H, Trestioreanu AZ, Yahav D, Leibovici L. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - A systematic review and meta-analysis. Clin Microbiol Infect. 2019 Mar;25(3):280-289. doi: 10.1016/j.cmi.2018.11.003. Epub 2018 Nov 23.</citation>
    <PMID>30472427</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>Christian Omar Ramos-Peñafiel, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Febrile Neutropenia</keyword>
  <keyword>Simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All participants and their information will be managed by intern investigators and will be kept secure for personal data protection according to Mexican laws.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

